nodes	percent_of_prediction	percent_of_DWPC	metapath
Ethosuximide—CYP3A43—Rifampicin—leprosy	0.426	0.43	CbGbCtD
Ethosuximide—CYP3A7-CYP3A51P—Rifampicin—leprosy	0.0621	0.0627	CbGbCtD
Ethosuximide—CYP3A7—Rifampicin—leprosy	0.0621	0.0627	CbGbCtD
Ethosuximide—CYP2E1—Thalidomide—leprosy	0.0619	0.0625	CbGbCtD
Ethosuximide—CYP2E1—Rifampicin—leprosy	0.0599	0.0605	CbGbCtD
Ethosuximide—CYP3A7-CYP3A51P—Dapsone—leprosy	0.0512	0.0518	CbGbCtD
Ethosuximide—CYP3A7—Dapsone—leprosy	0.0512	0.0518	CbGbCtD
Ethosuximide—CYP2E1—Dapsone—leprosy	0.0495	0.05	CbGbCtD
Ethosuximide—CYP3A5—Thalidomide—leprosy	0.0481	0.0486	CbGbCtD
Ethosuximide—CYP3A5—Rifampicin—leprosy	0.0466	0.047	CbGbCtD
Ethosuximide—CYP3A5—Dapsone—leprosy	0.0384	0.0388	CbGbCtD
Ethosuximide—CYP3A4—Rifampicin—leprosy	0.0182	0.0183	CbGbCtD
Ethosuximide—CYP3A4—Dapsone—leprosy	0.015	0.0151	CbGbCtD
Ethosuximide—Psychotic disorder—Dapsone—leprosy	0.000543	0.0533	CcSEcCtD
Ethosuximide—Aplastic anaemia—Thalidomide—leprosy	0.000368	0.0361	CcSEcCtD
Ethosuximide—Hyperkinesia—Thalidomide—leprosy	0.000342	0.0335	CcSEcCtD
Ethosuximide—Mental disability—Thalidomide—leprosy	0.00034	0.0334	CcSEcCtD
Ethosuximide—Euphoric mood—Thalidomide—leprosy	0.000337	0.033	CcSEcCtD
Ethosuximide—Lethargy—Thalidomide—leprosy	0.00029	0.0285	CcSEcCtD
Ethosuximide—Disturbance in sexual arousal—Thalidomide—leprosy	0.000282	0.0277	CcSEcCtD
Ethosuximide—Psychotic disorder—Thalidomide—leprosy	0.000278	0.0273	CcSEcCtD
Ethosuximide—Ataxia—Thalidomide—leprosy	0.000268	0.0263	CcSEcCtD
Ethosuximide—Breast disorder—Thalidomide—leprosy	0.000257	0.0252	CcSEcCtD
Ethosuximide—Cramp muscle—Thalidomide—leprosy	0.000256	0.0251	CcSEcCtD
Ethosuximide—Eosinophilia—Thalidomide—leprosy	0.000244	0.0239	CcSEcCtD
Ethosuximide—Pancytopenia—Thalidomide—leprosy	0.000234	0.0229	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Dapsone—leprosy	0.000223	0.0219	CcSEcCtD
Ethosuximide—Weight decreased—Thalidomide—leprosy	0.000223	0.0218	CcSEcCtD
Ethosuximide—Drowsiness—Thalidomide—leprosy	0.000219	0.0215	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Thalidomide—leprosy	0.000217	0.0213	CcSEcCtD
Ethosuximide—Abdominal pain—Dapsone—leprosy	0.000216	0.0212	CcSEcCtD
Ethosuximide—Haematuria—Thalidomide—leprosy	0.000209	0.0205	CcSEcCtD
Ethosuximide—Agranulocytosis—Thalidomide—leprosy	0.000205	0.0201	CcSEcCtD
Ethosuximide—Urinary tract disorder—Thalidomide—leprosy	0.000194	0.0191	CcSEcCtD
Ethosuximide—Urethral disorder—Thalidomide—leprosy	0.000193	0.0189	CcSEcCtD
Ethosuximide—Erythema multiforme—Thalidomide—leprosy	0.000186	0.0183	CcSEcCtD
Ethosuximide—Eye disorder—Thalidomide—leprosy	0.000184	0.018	CcSEcCtD
Ethosuximide—Immune system disorder—Thalidomide—leprosy	0.000178	0.0174	CcSEcCtD
Ethosuximide—Mediastinal disorder—Thalidomide—leprosy	0.000177	0.0174	CcSEcCtD
Ethosuximide—Vomiting—Dapsone—leprosy	0.000174	0.017	CcSEcCtD
Ethosuximide—Mental disorder—Thalidomide—leprosy	0.000172	0.0169	CcSEcCtD
Ethosuximide—Malnutrition—Thalidomide—leprosy	0.000171	0.0168	CcSEcCtD
Ethosuximide—Headache—Dapsone—leprosy	0.000171	0.0168	CcSEcCtD
Ethosuximide—Muscle spasms—Thalidomide—leprosy	0.000165	0.0162	CcSEcCtD
Ethosuximide—Nausea—Dapsone—leprosy	0.000162	0.0159	CcSEcCtD
Ethosuximide—Agitation—Thalidomide—leprosy	0.000157	0.0154	CcSEcCtD
Ethosuximide—Leukopenia—Thalidomide—leprosy	0.000153	0.015	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.000145	0.0142	CcSEcCtD
Ethosuximide—Nervous system disorder—Thalidomide—leprosy	0.000137	0.0135	CcSEcCtD
Ethosuximide—Skin disorder—Thalidomide—leprosy	0.000136	0.0133	CcSEcCtD
Ethosuximide—Anorexia—Thalidomide—leprosy	0.000133	0.0131	CcSEcCtD
Ethosuximide—Somnolence—Thalidomide—leprosy	0.000124	0.0122	CcSEcCtD
Ethosuximide—Decreased appetite—Thalidomide—leprosy	0.000122	0.0119	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Thalidomide—leprosy	0.000121	0.0118	CcSEcCtD
Ethosuximide—Fatigue—Thalidomide—leprosy	0.000121	0.0118	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Thalidomide—leprosy	0.000114	0.0112	CcSEcCtD
Ethosuximide—Urticaria—Thalidomide—leprosy	0.000111	0.0109	CcSEcCtD
Ethosuximide—Abdominal pain—Thalidomide—leprosy	0.000111	0.0108	CcSEcCtD
Ethosuximide—Hypersensitivity—Thalidomide—leprosy	0.000103	0.0101	CcSEcCtD
Ethosuximide—Asthenia—Thalidomide—leprosy	0.0001	0.00984	CcSEcCtD
Ethosuximide—Diarrhoea—Thalidomide—leprosy	9.57e-05	0.00939	CcSEcCtD
Ethosuximide—Dizziness—Thalidomide—leprosy	9.25e-05	0.00907	CcSEcCtD
Ethosuximide—Vomiting—Thalidomide—leprosy	8.89e-05	0.00872	CcSEcCtD
Ethosuximide—Rash—Thalidomide—leprosy	8.82e-05	0.00865	CcSEcCtD
Ethosuximide—Dermatitis—Thalidomide—leprosy	8.81e-05	0.00864	CcSEcCtD
Ethosuximide—Headache—Thalidomide—leprosy	8.76e-05	0.0086	CcSEcCtD
Ethosuximide—Nausea—Thalidomide—leprosy	8.31e-05	0.00815	CcSEcCtD
